Expert in Stem cells, ischemia, stroke, cryopreservation, bioengineering, wound healing, inflammation, blood, vascular biology, cancer immunology
Previously Expert had a leading role in the development of new blood-derived products for wound healing in a startup company. Expert is using her previous experience in leukocyte activation, adhesion and inflammation (her thesis research and postdoctoral training resulting in 10 peer-reviewed publications and two patents) on a new industrial level. Prior to joining the company on a full-time basis Expert served as the company's freelance consultant. Overall Expert has been working with blood products for wound healing for almost four years. She co-authored 2 patents and contributed significantly to IND application to FDA and FDA correspondence.
Expert developed and executed an R&D program for upgrading her company's wound healing product for the treatment of solid tumors. The mechanism of action for a new product is based on concepts of tumor immunology. Based on this pipeline research a patent application with multiple experimental examples was submitted.
Expert led pioneering research of human embryonic stem cells (hES cells) at the National Institute on Aging, NIH for more than 3 years. She optimized and standardized hES culture conditions and conducted an analysis of hES cell markers on a protein and gene level. She established conditions for neuronal differentiation of hES cells. Her work resulted in 6 publications.
Expert has vast experience with mesenchymal stem cells (MSC). For 6 years she headed Cell Therapy Laboratory at Teva Pharmaceutical Industries in Israel. She developed and standardized conditions for differentiation of MSC into bone progenitors, osteoclasts, endothelial progenitors, and cardiac myocytes. Expert developed and patented a method for the production of bone progenitors growing on biodegradable scaffolds, such as collagen, polylactic acid (PLA), polyglycolic acid (PGA) polymers, hydrogels and others (published). She also developed assays for assessment of MSC viability, apoptosis, proliferation and osteogenic differentiation in a 2-D culture and on the scaffolds. She conducted several pre-clinical studies using bone marrow-derived bone progenitors growing on scaffolds for bone repair in critical size bone defect models.
Expert's lab performed an extensive analysis of MSC markers using microarrays, real-time PCR and flow cytometry. She identified several new markers that distinguish MSC from fibroblasts (published).
While working at Teva Pharmaceutical Industries as a Head of Cell Therapy Lab Expert established a GMP-grade cryopreservation method for MSC (published). She has developed multiple assays for testing cell viability, apoptosis and proliferation in order to evaluate freezing injury. In her current position as a Head of New Biotechnology, the expert is developing a cryopreservation protocol for the company's product using clinical grade cryoprotectants.
Expert has extensive experience in flow cytometry analysis of cells stained with specific antibodies against various cell markers, such as markers of undifferentiated embryonic stem cells and of neuronal differentiation (published work), markers of undifferentiated mesenchymal stem cells and fibroblasts and of osteogenic differentiation (published work), markers of lymphocytes, monocytes and granulocytes and activation markers of these leukocyte subsets (current work with a blood product for wound healing).
Expert has a vast knowledge of cell biology. She worked with primary cell cultures of many cell types (neurons, astrocytes, embryonic stem cells, bone marrow-derived stromal cells, fibroblasts) as well as tumor cell lines.
developed viability, cytotoxicity, apoptosis, proliferation, differentiation, adhesion and other biological assays to study the effects of activation, hypoxia and cryopreservation on these cell types.
While working as a Head of Cell Therapy Laboratory and as a Coordinator of the Israeli Stem Cell Consortium and currently as a Head of New Biotechnology Research in a startup company Expert developed detailed scientific programs long and short term and implemented these programs through experimental protocols and assay development. The protocols were adjusted based on extensive analysis of experimental data.
For 20 years Expert has been conducting research in various areas of cell biology, first in academia and then in industry. This research resulted in more than 30 publications and book chapters as well as in a number of patent families. Extensive literature search is a significant part of these activities. Literature search and analysis was performed for development and support of new hypotheses and ideas and for learning new methodology. Detailed citation lists accompany all Expert's publications, patent applications and R&D proposals.
Expert closely worked with patent lawyers on her patent applications. Three of her patents have been already published and three others are at various stages of the application process. In her current work Expert has been in charge of the company's IP working closely with the patent firms on patent drafts and updates.
Expert performed multiple peer reviews of scientific publications submitted to various journals such as Stem Cells and Development, Tissue Engineering, Cell Physiology and others. As a Coordinator of the Adult Stem Cell Cluster of the Israeli Consortium for Cell Therapy, Expert reviewed scientific programs submitted to Consortium for funding. Recently Expert participated in the review of Large Collaborative Project proposals submitted to European Commission Seventh Framework Programme (FP7) as an Expert Evaluator (wrote individual evaluation reports for allocated proposals) and Rapporteur (wrote consensus reports for a panel of experts).
From 1995 to 2001 Expert worked as a Senior Research Fellow at the Stroke Branch of NINDS, NIH. Her task was to establish cellular models of ischemia/reperfusion based on primary cultures of neurons and astrocytes. Expert studied molecular mechanisms of ischemic tolerance. Her experimental work led to the identification of ceramide as an intracellular signaling messenger for apoptotic neuronal death after ischemic brain injury. Ceramide in a lower dose, however, was implicated in the induction of tolerance to ischemia. These in vitro findings were further supported by animal studies showing the neuroprotective effect of ceramide in the permanent middle cerebral artery occlusion model of stroke and in the immature rat brain hypoxia-ischemia model of neonatal asphyxia. During her tenure at the Stroke Branch, Expert co-authored nine peer-reviewed papers and five review articles and book chapters. Expert supervised a number of postdoctoral and visiting fellows.
2008-2010 Consultant, Expert's firm: R&D program development; Expansion of IP; FDA correspondence; Government grant application
Expert may consult nationally and internationally, and is also local to the following cities: Boston, Massachusetts - Worcester, Massachusetts - Springfield, Massachusetts - Lowell, Massachusetts - Cambridge, Massachusetts - Brockton, Massachusetts - New Bedford, Massachusetts - Hartford, Connecticut - Manchester, New Hampshire - Providence, Rhode Island
|Year: 1991||Degree: PhD||Subject: Cell Biology and Pathology||Institution: Boston University School of Medicine|
|Year: 1980||Degree: MS/MD||Subject: Biochemistry/Medicine||Institution: Pirogov Moscow Medical Institute|
|Years: 2012 to Present||Employer: Undisclosed||Title: Founder||Department: Consulting||Responsibilities: Consulting services in pre-clinical and clinical product development, IND preparation, patent drafts, grant writing, mobile health applications.|
|Years: 2011 to Present||Employer: Undisclosed||Title: Panel Expert and Rapporteur||Department:||Responsibilities: Review and assessment of applications for funding from scientific consortia (universities, medical institutions, businesses) in the framework of European Commission Programs (the latest Horizon 2020) in the field of biomaterials, bioengineering, and regenerative medicine.|
|Years: 2017 to 2019||Employer: Cactus Global||Title: Freelance writer||Department:||Responsibilities: Medical and scientific writing based on client research data
|Years: 2010 to 2012||Employer: Macrocure||Title: Head, New Biotechnology Research||Department: startup||Responsibilities: Cryopreservation of the current product
Product pipeline, new indications
|Years: 2004 to 2010||Employer: Teva Pharmaceutical Industries, Israel||Title: Head; Associate Director||Department: Cell Therapy Lab||Responsibilities: Established an adult stem cell laboratory.
Developed and standardized assays for differentiation of mesenchymal stem cells (MSC); QC assays; transportation conditions.
GMP-grade cryopreservation program for suspended and scaffold-seeded MSC.
Developed and patented a new method for isolation of bone progenitors from unprocessed bone marrow.
Novel MSC markers and markers of osteogenic differentiation: real time PCR, microarrays; FACSAria.
Preclinical studies: critical size calvarial and long bone defect models of bone repair in rodents
|Years: 2002 to 2004||Employer: National Institute of Ageing, NIH,||Title: Scientist, Stem Cells||Department: Laboratory of Neurosciences||Responsibilities: Established human embryonic stem cell laboratory
Standardization of human embryonic cell culture.
Human embryonic stem cell gene and protein markers
Adviser for Postdoctoral and Visiting Fellows
|Years: 2001 to 2002||Employer: National Institute of Neurological Disorders and Stroke (NINDS)||Title: Senior Research Fellow||Department: Laboratory of Molecular Biology||Responsibilities: Experimental work: effect of hypoxia on mouse embryonic stem cell differentiation|
|Years: 1996 to 2001||Employer: National Institute of Neurological Disorders and Stroke (NINDS)||Title: Senior Research Fellow||Department: Stroke Branch||Responsibilities: Established cell culture facilities
Cellular models (neurons, astrocytes) of of ischemia and ischemic tolerance.
Adviser for Postdoctoral and Visiting Fellows
|Years: 1994 to 1996||Employer: Boston University School of Medicine||Title: Instructor||Department: Pathology Department||Responsibilities: Experimental work: leukocyte-endothelial interactions, inflammation, hypoxic injury
|Years: 1991 to 1994||Employer: Boston University School of Medicine||Title: Postdoctoral Fellow||Department: Cancer Research Center||Responsibilities: Experimental work: leukocyte-endothelial interactions, inflammation, hypoxic injury
|Years: 1990 to 1991||Employer: Dana Farber Cancer Institute, Harvard Medical School||Title: Postdoctoral Fellow||Department: Pediatric Oncology||Responsibilities: Experimental work: leukocyte-endothelial interactions, inflammation, hypoxic injury
|Years: 2011 to Present||Agency: European Commission; Seventh Framework Programme (FP7), Horizon 2020||Role: Expert Evaluator and Rapporteur||Description: Large Collaborative Project proposals in "Nanosciences, Nanotechnologies, Materials and New Production Technologies"•Writing individual evaluation reports for allocated proposals.•Writing consensus reports for a panel of experts.|
|Years: 2004 to 2010||Agency: Chief Scientist’s Office of the Israeli Ministry of Industry & Trade||Role: Coordinator of the Adult Stem Cell Cluster; Israeli Consortium for Cell Therapy||Description: Development of a scientific program for adult stem cell cluster of the Consortium; •Preparation of quarterly reports of the program execution.•Organization of scientific seminars for the Consortium members; establishment of scientific collaborations between academic and industrial members of the Consortium|
|Years: 2002 to 2004||Agency: National Institute of Ageing, NIH||Role: Staff Scientist||Description: Established human embryonic stem cell facilities and program|
|Years: 1996 to 2002||Agency: National Institute of Neurological Disorders and Stroke, NIH||Role: Senior Research Fellow||Description: Conducted research in the area of stroke injury|
|Years||Country / Region||Summary|
|Years: 2004 to 2012||Country / Region: Israel||Summary: Teva Pharmaceutical Industries, Head Stem Cell Therapy; Macrocure LTD; Coordinator of the Adult Stem Cell Cluster; Israeli Consortium for Cell Therapy|
|Associations / Societies|
|International Society for Stem Cell Research (ISSCR)
Israel Stem Cell Society (ISCS)
|Member of Editorial Board, Advances in Wound Care, a bimonthly journal (ISSN: 2162-1918) in the field of tissue injury and repair, with an emphasis on acute and chronic wound care to optimize patient outcomes.|
|Medical / Professional|
|1980; MD; the 2nd Moscow State Medical Institute named after N.I. Pirogov.
1980-1984; Clinician-Biochemist; Kidney Transplantation Center; Moscow City Clinical Hospital No. 1; Publication: Lopatkin NA, Chudnovskaia MV, Nenasheva NP, Rodoman VE, Expert IV. Urol Nefrol (Mosk). [Biochemical characteristics and treatment of chronic pyelonephritis in the clinical remissions phase]. 1978 Mar-Apr;(2):3-7. [Article in Russian]
2013-current; Adviser, mobile health applications: obesity, metabolic syndrome, CVD, healthy lifestyle
|Publications and Patents Summary|
|Expert has more than 30 peer-reviewed publications and book chapters, first author of 5 patents, co-author of other 2 patent families|
|Training / Seminars|
|Coordinator, Adult Stem Cell Cluster and Tools Development Cluster
Israeli Consortium for Cell Therapy: program development; organization of scientific seminars
Biochemistry Instructor, Biomedical Sciences Program, Metropolitan College, Boston University, Boston, MA
|Other Relevant Experience|
|Technical writing: patent applications, IND application, scientific proposals, grant applications|
|Russian||Mother tongue. Excellent oral and written skills; Review of the scientific literature, scientific collaborations|
|English||The highest level of oral and written skills; multiple scientific writings, peer reviews, patent applications, presentations at international conferences|